Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

THY1 (Thy-1 cell surface antigen)

Written2010-01John E Bradley, James S Hagood
Departments of Pediatrics, Biochemistry, Molecular Genetics, University of Alabama-Birmingham, AL, USA (JEB); Department of Pediatrics, University of California at San Diego, USA (JSH)

(Note : for Links provided by Atlas : click)


Alias (NCBI)CD90
HGNC (Hugo) THY1
HGNC Alias symbCD90
LocusID (NCBI) 7070
Atlas_Id 45672
Location 11q23.3  [Link to chromosome band 11q23]
Location_base_pair Starts at 119415476 and ends at 119423172 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping THY1.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)


  Organization of the human THY1 gene and control elements. There are sequences conferring tissue specificity for the brain in the first intron and kidney in the third intron.
Description 4 exons; DNA size: 5591.
Transcription Transcription of THY1 is initiated at multiple sites producing an approximately 5591 bp transcript. After splicing, the transcript is reduced to 2143 bp. Transcriptional regulation for tissue-specific expression of Thy-1, as well as for controlling expression in cell sub-populations, and in some cancers, is governed by a number of mechanisms. For tissue-specific transcriptional regulation, the regulatory elements are found exclusively downstream of the transcription initiation site within the gene itself. Differential tissue expression of Thy1 exists between species as closely related as mouse and rat. For example, Thy1 is expressed in mouse thymocytes and splenocytes, but only thymocytes in rat. The absence of Thy1 in rat splenocytes is attributed to a three nucleotide difference in a conserved 36 bp region within the third intron. In mice, this 36 bp region can bind an Ets-l-like nuclear factor expressed by both mouse thymocytes and splenocytes. In rats, the three nucleotide difference renders the 36 bp region no longer capable of binding the similar Ets-l-like nuclear factor expressed by rats. However, rat thymocytes but not splenocytes express another nuclear factor which does recognize the 36 bp region and this is thought to account for the expression of Thy1 in rat thymocytes but not splenocytes. In humans, THY1 is detected in the brain, spleen, kidneys, but not thymus. In mouse, Thy1 is detected in the brain, spleen, thymus, but not kidneys. In transgenic mice, deletion of half the 3' end of intron 1 prevents expression of Thy1 in the brain but allows for its expression in the thymus. The control elements within the first intron of Thy-1 are conserved in human and mouse, as replacement of the first intron in mouse with that from human causes no detectable change in Thy1 expression in the brain. Differences between intron 3 of mouse and human Thy-1 seem to account for expression of Thy-1 in human but not mouse kidney and mouse but not human thymus. In transgenic mice, Thy1 is no longer expressed in the thymus but ectopically expressed in the kidney when the third intron of mouse Thy1 is replaced with the third intron of human THY1. The aforementioned downstream control elements require at a minimum 300 bp of the endogenous Thy1 promoter for transcription to occur. Interestingly, the endogenous Thy1 promoter in itself does not elicit transcription or tissue specificity absent the downstream elements. Conversely, the downstream elements are able to direct tissue-specific transcription of Thy1 with a heterologous promoter. Therefore, the downstream control elements are "promiscuous" with regard to a promoter, while the endogenous promoter is "monogamous" with the downstream control elements. The validity of these assertions is exemplified in the design of the murine thy1.2 genomic expression cassette for driving expression in the nervous system. In this cassette, the coding sequences, as well as the third intron of thy1.2 have all been removed, but the first intron is retained.
Suppression of Thy-1 transcription within sub-populations of lung fibroblasts and the tumorigenic nasopharyngeal cell carcinoma (NPC) cell line HONE1 is shown to occur via hypermethylation of CpG (cytosine-guanine) islands in the Thy-1 gene promoter. Moreover, THY1 is thought to function as a tumor suppressor in NPC as microcell-mediated transfer of an additional intact human chromosome 11 into HONE1 cells decreases colony formation with re-expression of THY1. Tumor segregants of the HONE1 microcell hybrids were all negative for THY1. Concurrently, the region 11q22-23 is shown to be critical for tumorigenicty in NPC. In both rat and human lung fibroblasts, CpG islands in the Thy-1 gene promoter are hypermethylated in the Thy-1 negative fibroblast subpopulation but not in the positive. Thy1 expression is induced in Thy1 (-) fibroblasts by treatment with 5-aza-2'-deoxycytidine, a DNA methyltransferase inhibitor. Suppression of THY1 transcription via hypermethylation of its promoter in THY1 (-) lung fibroblasts has implications in the disease idiopathic pulmonary fibrosis (IPF). Fibroblastic foci are populated predominantly by THY1 (-) myofibroblasts and methylation-specific PCR-in situ hybridization has demonstrated THY1 promoters within these areas to be hypermethylated.


  THY1 molecule and proposed soluble forms. THY1 is initially generated as a 161 aa pro form. The initial 19 aa signal peptide is removed, and the terminal 31 aa are replaced with a GPI anchor, generating the mature form, which is anchored to the outer leaflet of the cell membrane by the diacyl group of the GPI anchor. N-linked glycosylation sites depict conserved asparagines within murine Thy1 that are known to be glycosylated. Soluble Thy-1 could be generated either by cleavage of the GPI anchor by GPI-PLD, or by undefined proteases acting at as yet undetermined cleavage sites.
Description Human and mouse Thy-1 are both initially translated as a 161 and 162 amino acid pro-form, respectively. In mouse, there are two alleles that encode two proteins distinguished by having either arginine or glutamine at position 89. Humans have only one allele of THY1. The first 19 aa of the pro-form are a localization signal that targets it into the ER. Initially, the c-terminal residues 131-161 function as a trans-membrane domain within the ER. Thy-1 undergoes several post translation modifications, including proteolytic cleavage, N-linked glycosylation, and addition of a GPI moiety. The localization signal and trans-membrane domain are proteolytically cleaved away leaving a core protein composed of residues 20-131. The N-linked glycosylation sites of murine Thy1 are at asparagine residues 42, 94, and 118. Only two of these residues are conserved in human at positions 42 and 119. The carbohydrate content of THY1 accounts for nearly 30% of its molecular mass, which ranges from 25 to 37 kDa. Between species, tissue types, and cells in different stages of development: these carbohydrate moieties may vary dramatically. After removal of the trans-membrane domain, a GPI moiety is attached to the c-terminal residue of the core protein, cysteine 130. The GPI moiety contains two fatty-acyl groups that embed into the membrane thereby anchoring Thy-1 to the cell surface. Thus, Thy-1 has no intra-cellular domain. Thy-1 is a member of the immunoglobulin superfamily and as such possesses cysteine residues which form disulfide bonds. A soluble variety of Thy-1 exists and is presumably produced by a proteolytic and/or lipolytic cleavage at the cell surface. If the latter is the case, it is presumed to occur in close proximity to the c-terminus. Completely deglycosylated membranous and soluble THY1 have indistinguishable migration speeds through a polyacrylamide gel.
Expression In mouse and human, Thy-1 is expressed at the cell surface of mature neurons, a subset of fibroblasts, and activated natural killer cells. With the exception of these cell types, mouse and human each have unique Thy-1 expression profiles. Thy1 covers up to 10-20% of mouse thymocyte cell surface but levels diminish in locations of greater thymocyte maturation. Specifically, cortical thymocytes express higher levels of Thy1 than medullary thymocytes and Lymph node cells have levels less than both. The only human thymocytes to express THY1 are a small population of cortical thymocytes, whereas expression of Thy1 in the mouse is broader and also includes peripheral T cells. In humans, THY1 is also expressed by endothelial cells (conditionally), smooth muscle cells, some glial cells, a subset of CD34 (+) bone marrow cells, and umbilical cord blood- and fetal liver-derived hematopoietic stem cells.
A soluble variety of THY1 is detectable in serum, cerebral spinal fluid, wound fluid from venous leg ulcers, and the synovial fluid from joints in rheumatoid arthritis. Cultured lung fibroblasts shed THY1 into the media when treated with pro-inflammatory cyokines, such as IL-1beta and TNF-alpha. The opposite effect is elicited in endothelial cells, in which pro-inflammatory cytokines stimulate increased THY1 expression.
Relative to the neonatal and developing brain, the adult brain expresses far greater levels of THY1. Moreover, postnatal increase in Thy-1 expression coincides strongly with histological and physiological indicators of brain maturation. Thus, expression of Thy-1 is developmentally regulated in the brain. As the brain develops, expression of Thy1 mRNA precedes detection of protein by several days, thereby suggesting post-transcription regulation of Thy-1 mRNA as a mechanism for controlling temporal expression of Thy-1 protein in the developing brain. This mode of regulation has been shown to be an intrinsic attribute of immature neurons. Mature Thy1.1-expressing neurons fused with immature Thy1.2-negative neurons to form heterokaryons become Thy1 negative within 16 h. As factors that maintained the immature condition of the Thy1.2 negative neuron counterpart presumably give way, the heterokaryons express both Thy1.1 and Thy1.2 within 3-4 days after becoming negative. This suggests that a developmentally regulated diffusible suppressor molecule inhibits translation of the Thy1 protein in immature neurons. This method of regulation is perhaps a means to forgo the time needed to transcribe Thy-1 mRNA and thereby prime the immature neuron for immediate expression of Thy-1 protein to coincide with maturation. In response to injury, Thy1 expression in mature neurons mimics that of a developing neuron. In young adult rats, Thy1 expression dramatically decreases in dorsal root ganglion neurons two days post a crush injury of the sciatic nerve reaching a low around day four. Thy1 expression gradually returns to pre-injury levels 1 week after the sciatic nerve crush and coincides with recovery of sensory function. Central nervous system neurons do not have the same potential to recover from traumatic injury as peripheral nervous system neurons do. Response to traumatic injury by central nervous system ganglion cells also differs with respect to Thy1 expression. Specifically, optic nerve crush results in cell loss due to apoptosis after 2 weeks. Prior to any cell loss, levels of Thy1 mRNA decrease over the course of 7 days with no change in the number of Thy1 expressing cells. This suggests the decrease in Thy1 mRNA is an injury response rather than a consequence of apoptosis. The optic ganglion cells of Bax knockout mice are resistant to cell death following optic nerve crush. Despite this, the same decrease in Thy1 mRNA is observed following optic nerve crush in Bax knockout mice. Additional means of optic nerve injury also cause a decrease in Thy1 mRNA levels including intravitreal injections of N-methyl-D-aspartate and induced elevated intraocular pressure.
Localisation At the cell surface, Thy-1, like many GPI anchored proteins, localizes to cholesterol-rich lipid rafts. Release of Thy-1 into the extracellular space and into body fluids, such as serum and cerebral spinal fluid, occurs via unknown mechanisms. In-vitro, both mammalian GPI-PLD and bacterial PLC are capable of separating the diacyl glycerol from the remainder of the GPI-moiety. When Thy-1 is released from the cell surface by GPI-PLD the phosphate is not retained, but is when released by PLC. In order for Thy-1 to be susceptible to release by GPI-PLD, lipid rafts must be disrupted by detergents or saponins. PLC has no such requirement. However, Thy1 in certain cell types is more resistant to PLC. Thus, Thy-1 is thought to be afforded some protection from GPI-PLD catalyzed release by its localization within lipid rafts.
For Thy-1 to signal, it must be localized to its native lipid raft microdomain. Thy1 (-) neurons grown on a monolayer of astrocytes and expressing exogenous human THY1 or mouse Thy1.2 experienced inhibited neurite outgrowth. Yet under the same conditions, Thy1 (-) neurons expressing a construct of Thy1 in which the GPI anchor is replaced by the transmembrane domain of CD8 have normal neurite outgrowth. The transmembrane domain of CD8 does not localize Thy1 to lipid raft microdomains. This same construct was later used in experiments to assess the role of the Thy1 GPI anchor in modulating fibroblast phenotypes. Not unlike the results in the neuron experiments, Thy1 (-) fibroblasts made to express the Thy1-CD8 construct maintained their "negative" phenotype in that they remained insensitive to thrombospondin-mediated transient phosphorylation of FAK and SFK, focal adhesion disassembly, and migration.
Function The Thy1 antigen was initially discovered in an attempt to raise antiserum against leukemia-specific antigens from the CH3 mouse strain in the AKR mouse strain and vice versa. The antibodies were found to strongly label thymocytes as well as peripheral T cells, hence the name Thy1. Thy-1 has several immunological functions, most mediated through interactions with integrins. In particular, Thy1 binds integrins alphaMbeta2 and alphaXbeta2 which are both expressed by leukocytes. In cell adhesion assays, monocytes and polymorphonuclear cells adhere to exogenous Thy1-expressing CHO cells and activated THY1-expressing Human Dermal Microvascular Endothelial Cells (HDMECs). This adherence was found to be mediated by the interaction between THY1 and alphaMbeta2. Antibodies against alphaMbeta2 blocked adherence, while exogenously expressing alphaMbeta2 but not control CHO cells are able to retain biotynilated purified THY1 at their cell surface. Moreover, the interaction of THY1 with alphaMbeta2 was found to be vital in transendothelial migration of the aforementioned leukocytes across a monolayer of HDMECs. Thereby, THY1 is implicated in the regulation of leukocyte recruitment to sites of inflammation.
Early evidence showed surface Thy1 expression diminishes as thymocytes mature into T cells, suggesting a role for Thy-1 in regulating thymocyte lineage. Thymocytes from Thy1 null mice have a reduced maturation rate from the immature CD4+CD8+ double-positive to the CD4+ or CD8+ single-positive mature T cell. Thy1 supports adhesion of thymocytes to thymic epithelial cells. Accordingly, the contacts between thymus cells of the Thy1 null mice are atypical as evaluated by electron microscopy. The role of Thy-1 in thymocyte adhesion and maturation may not be mutually exclusive. Thy1 seems to have a continued role in T cell activity beyond maturation from thymocytes. Cross-linking Thy1 using bivalent antibodies against Thy1 results in T cell activation as indicated by proliferation and IL-2 synthesis. It is important to note there is no known ligand for Thy-1 that the cross-linking antibody presumably mimics. Traditionally, activation of a T cell is thought to require two simultaneous signals. One is a B7 family member engaging T cell CD28 receptor and the other is the T cell receptor being presented its specific antigen by an MHC. Cross-linking Thy1 with antibodies partially supplies the latter signal to activate T cells when the CD28 receptor is engaged by anti-CD28 antibodies. The activation is only partial because, although the T cells adhere to target cells and express perforin, granzyme B, and Fas ligand, they are unable to kill target cells. The specific role Thy1 has in T cell activation and thymocyte maturation in vivo, and whether they are related is unknown.
Thy-1 expression modulates fibroblast phenotype. Pulmonary fibroblasts sorted into Thy-1 (+) and (-) populations have dissimilar potential for differentiating into myofibroblasts, response to pro-inflammatory cytokines, and localization into areas of active fibrosis. Rat Thy1 (-) pulmonary fibroblasts have greater myofibroblastic differentiation relative to Thy1 (+) as assessed by contractility and myogenic gene expression of MyoD, myocardin, myf5, and myogenin, both at baseline and in response to fibrogenic mediators. In addition, Thy1 (-) fibroblasts resist apoptosis in a contracting collagen matrix. Thy1 (+) and (-) pulmonary fibroblasts have dissimilar production of and/or responses to various cytokines. In response to PDGF-BB, both populations undergo concentration-dependent proliferation. However, only the Thy1 (-) population proliferates in response to PDGF-AA. Consistent with the proliferation assays, both populations express PDGFR-beta. Only Thy1 (-) pulmonary fibroblast express PDGFR-alpha. Thrombospondin-1 or its N-terminal heparin-binding domain alone is a potent inducer of cell migration. Coordinated focal adhesion disassembly is critical for cell migration to occur. Thy1 (+) but not Thy1 (-) pulmonary fibroblasts respond to Thrombospondin-1/HEP-I with transient phosphorylation of FAK and SFK, focal adhesion disassembly, and migration. Exogenous expression of WT Thy1 by Thy1 (-) pulmonary fibroblasts creates sensitivity to Thrombospondin-1/HEP-I. It is important to note that as for other described functions of Thy-1, localization of Thy-1 within lipid rafts is required (see Localisation, above). Thy1 (-) pulmonary fibroblasts, in contrast to Thy1 (+), are capable of activating latent TGF-beta. Only Thy1 (-) murine pulmonary fibroblasts produce IL-1 in response to TNF-alpha. Moreover, proliferation and IL-6 expression induced by IL-1beta treatment is greater in Thy1 (-) cells relative to Thy1 (+). Phenotypes attributed to the Thy1 (-) and Thy1 (+) fibroblast population of one tissue may be different or reversed in those from another tissue. Unlike in the lung, only THY1 (+) orbital fibroblasts appear capable of differentiating into myofibroblasts, whereas THY1 (-) are incapable of doing so but are unique in their ability to differentiate into mature adipocytes. Thus, the effects of THY1 on cell signaling are likely to be context-dependent.
Purified Thy1 immobilized on microbeads has been shown to bind integrin beta3 on astrocytes causing them to form focal adhesion sites. However, inhibition of neurite outgrowth in Thy1 expressing neurons is not believed to require induced focal adhesion formation or factors emanating from the astrocytes. Thy1 (-) neurons expressing a construct of Thy1 at the cell surface that does not localize to lipid rafts and grown on a monolayer of astrocytes are capable of normal neurite outgrowth. Despite Thy1 being able to engage integrin beta3 on the astrocyte, neurite outgrowth is not inhibited. Thy1 requires correct localization to its native membrane micro domain to exert an inhibitory effect which suggests that Thy1 functions as a receptor of the neuron rather than a ligand for the astrocyte. Remarkably, Thy1 deficient mice have only subtle nervous system irregularities, including inhibition of hippocampal long-term potentiation in the dentate gyrus and failure to transmit social cues regarding food selection.

Implicated in

Entity Nasopharyngeal carcinoma
Note In nasopharyngeal carcinoma, THY1 is believed to function as a tumor suppressor. The tumorigenic NPC cell line, HONE1, decrease colony formation with addition of an intact chromosome 11 via microcell-mediated transfer and coincides with reexpression of THY-1. The THY1 gene is located within region 11q22-23 which is critical for tumorigenicity in NPC. Additionally, tumor segregants of the HONE1 microcell hybrids were all negative for THY1. THY1 expression is decreased in more invasive/metastatic NPC and this is thought to occur via epigenetic silencing.
Entity Ovarian cancer
Note The loss of heterozygosity at 11q23.3-q24.3 for patients with ovarian cancer is associated with poor prognosis. This region of chromosome 11 contains the THY1 gene. THY1 expression in the tumorigenic ovarian cancer cell line, SKOV-3, induced by either microcell-mediated chromosome 11 transfer or THY1 expression inducible system suppresses tumorigenicity.
Entity Idiopathic pulmonary fibrosis (IPF)
Note Evidence from both in vivo and in vitro experiments implicates loss of fibroblast THY1 is important in the disease Idiopathic Pulmonary Fibrosis (IPF). The most characteristic histopathologic feature of IPF is aggregates of proliferating fibroblasts and myofibroblasts called fibrotic foci. The number of FF directly correlates with severity of the disease. Though the vast majority of quiescent lung fibroblasts are THY1 positive, FF are exclusively occupied by THY1 (-) myofibroblasts. Thy1 (-) lung fibroblasts have a more fibrotic phenotype including response to profibrotic cytokines and propensity to differentiate into myofibroblasts. Moreover, the chemically induced model for lung fibrosis, intra-tracheal administered bleomycin, is more severe in Thy1 knockout mice with respect to accumulation of myofibroblasts, collagen, and increased activation of TGF-beta. THY1 expression has been shown to be epigenetically silenced by DNA hypermethylation in fibroblasts from IPF lesions in vivo and in vitro.
Prognosis The prognosis for a patient with IPF is almost universally poor, with a mean survival of only 2 to 4 years after diagnosis. Onset of the disease and subsequent diagnosis usually occur after the age of 50. Over the course of the disease, patients suffer severe dyspnea. For the estimated 40000 to 130000 IPF patients in the United States, there is no medical intervention that affords a survival benefit save for a lung transplant.
Entity Experimental glomerulonephritis
Note Intravenous administration of crosslinking anti-Thy1 antibodies to rats induces glumerulonephritis and serves as a model for study of the disease. The use of Thy1 antibodies for this purpose is supported by in vitro experiments. Cross linking Thy1 expressed on glomerular mesangial cells with anti-Thy1 antibodies induces apoptosis as confirmed by TdT-mediated dUTP nick-end labeling (TUNEL) and annexin V assays. Glumerulonephritis induced with anti-Thy1 antibodies in vivo has recently been shown to result from the combination of complement-mediated necrosis as well as apoptosis.
Entity Graves'ophthalmopathy (GO)
Note GO is characterized by an increase in volume of the extraocular muscles and/or the intraorbital adipose tissues which causes the eyeball to bulge from the orbit. Intraorbital fibroblasts, including those that reside around and within the extraocular muscles, have a pathogenic role in this disease. The THY1 (+), but not the THY1 (-), orbital fibroblast subpopulation differentiates into myofibroblasts as indicated by alpha-smooth muscle actin expression. The opposite is true for differentiation into lipofibroblasts assessed by accumulation of cytoplasmic lipid droplets. The orbital adipose/connective tissue taken from GO patients was shown to have greater THY1 mRNA and protein expression relative to the same tissue retrieved from individuals with no history of Graves'disease whose corneas were being procured for transplantation. Fibroblasts cultured from these two tissue sources were examined for THY1 expression. As with total tissue levels, there was greater expression of THY1 by fibroblasts cultured from tissue obtained from GO patients.


Ontogeny of murine T lymphocytes. I. Maturation of thymocytes induced in vitro by tumor necrosis factor-positive serum (TNF+)1,2.
Abbott J, Doyle PJ, Ngiam K, Olson CL.
Cell Immunol. 1981 Jan 1;57(1):237-50.
PMID 6971158
The role of the THY1 gene in human ovarian cancer suppression based on transfection studies.
Abeysinghe HR, Pollock SJ, Guckert NL, Veyberman Y, Keng P, Halterman M, Federoff HJ, Rosenblatt JP, Wang N.
Cancer Genet Cytogenet. 2004 Feb;149(1):1-10.
PMID 15104276
Characterization of a hydrophilic form of Thy-1 purified from human cerebrospinal fluid.
Almqvist P, Carlsson SR.
J Biol Chem. 1988 Sep 5;263(25):12709-15.
PMID 2900838
Chemical characterisation of the Thy-1 glycoproteins from the membranes of rat thymocytes and brain.
Barclay AN, Letarte-Muirhead M, Williams AF, Faulkes RA.
Nature. 1976 Oct 14;263(5578):563-7.
PMID 62283
Localization of the Thy-1 antigen in the cerebellar cortex of rat brain by immunofluorescence during postnatal development.
Barclay AN.
J Neurochem. 1979 Apr;32(4):1249-57.
PMID 372497
Thrombospondin-1-induced focal adhesion disassembly in fibroblasts requires Thy-1 surface expression, lipid raft integrity, and Src activation.
Barker TH, Pallero MA, MacEwen MW, Tilden SG, Woods A, Murphy-Ullrich JE, Hagood JS.
J Biol Chem. 2004 May 28;279(22):23510-6. Epub 2004 Mar 18.
PMID 15033989
Saponin-induced release of cell-surface-anchored Thy-1 by serum glycosylphosphatidylinositol-specific phospholipase D.
Bergman AS, Carlsson SR.
Biochem J. 1994 Mar 15;298 Pt 3:661-8.
PMID 7908190
Roles and regulation of Thy-1, a context-dependent modulator of cell phenotype.
Bradley JE, Ramirez G, Hagood JS.
Biofactors. 2009 May-Jun;35(3):258-65. (REVIEW)
PMID 19422052
Characterization of transgene expression and Cre recombinase activity in a panel of Thy-1 promoter-Cre transgenic mice.
Campsall KD, Mazerolle CJ, De Repentingy Y, Kothary R, Wallace VA.
Dev Dyn. 2002 Jun;224(2):135-43.
PMID 12112467
Role of Thy-1 in in vivo and in vitro neural development and regeneration of dorsal root ganglionic neurons.
Chen CH, Wang SM, Yang SH, Jeng CJ.
J Cell Biochem. 2005 Mar 1;94(4):684-94.
PMID 15547945
Characterization of alphaX I-domain binding to Thy-1.
Choi J, Leyton L, Nham SU.
Biochem Biophys Res Commun. 2005 Jun 3;331(2):557-61.
PMID 15850796
The glycan processing and site occupancy of recombinant Thy-1 is markedly affected by the presence of a glycosylphosphatidylinositol anchor.
Devasahayam M, Catalino PD, Rudd PM, Dwek RA, Barclay AN.
Glycobiology. 1999 Dec;9(12):1381-7.
PMID 10561463
Structure of the murine Thy-1 gene.
Giguere V, Isobe K, Grosveld F.
EMBO J. 1985 Aug;4(8):2017-24.
PMID 2866091
T cell-activating properties of an anti-Thy-1 monoclonal antibody. Possible analogy to OKT3/Leu-4.
Gunter KC, Malek TR, Shevach EM.
J Exp Med. 1984 Mar 1;159(3):716-30.
PMID 6142077
Thy-1: more than a mouse pan-T cell marker.
Haeryfar SM, Hoskin DW.
J Immunol. 2004 Sep 15;173(6):3581-8. (REVIEW)
PMID 15356100
Differential expression of platelet-derived growth factor-alpha receptor by Thy-1(-) and Thy-1(+) lung fibroblasts.
Hagood JS, Miller PJ, Lasky JA, Tousson A, Guo B, Fuller GM, McIntosh JC.
Am J Physiol. 1999 Jul;277(1 Pt 1):L218-24.
PMID 10409250
Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis.
Hagood JS, Prabhakaran P, Kumbla P, Salazar L, MacEwen MW, Barker TH, Ortiz LA, Schoeb T, Siegal GP, Alexander CB, Pardo A, Selman M.
Am J Pathol. 2005 Aug;167(2):365-79.
PMID 16049324
Thy-1 supports adhesion of mouse thymocytes to thymic epithelial cells through a Ca2(+)-independent mechanism.
He HT, Naquet P, Caillol D, Pierres M.
J Exp Med. 1991 Feb 1;173(2):515-8.
PMID 1671083
T-lymphocyte differentiation is accompanied by increase in sialic acid content of Thy-1 antigen.
Hoessli D, Bron C, Pink JR.
Nature. 1980 Feb 7;283(5747):576-8.
PMID 6965519
Thymocytes in Thy-1-/- mice show augmented TCR signaling and impaired differentiation.
Hueber AO, Bernard AM, Battari CL, Marguet D, Massol P, Foa C, Brun N, Garcia S, Stewart C, Pierres M, He HT.
Curr Biol. 1997 Sep 1;7(9):705-8.
PMID 9285719
Interleukin-1alpha regulates Thy-1 expression on rat vascular endothelial cells.
Ishizu A, Ishikura H, Nakamaru Y, Kikuchi K, Koike T, Yoshiki T.
Microvasc Res. 1997 Jan;53(1):73-8.
PMID 9056477
Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves' ophthalmopathy.
Khoo TK, Coenen MJ, Schiefer AR, Kumar S, Bahn RS.
Thyroid. 2008 Dec;18(12):1291-6.
PMID 18976167
T-cell regulation: Thy-1 - hiding in full view.
Killeen N.
Curr Biol. 1997 Dec 1;7(12):R774-7. (REVIEW)
PMID 9382830
Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes.
Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP.
Am J Pathol. 2003 Oct;163(4):1291-300.
PMID 14507638
Perimysial fibroblasts of extraocular muscle, as unique as the muscle fibers.
Kusner LL, Young A, Tjoe S, Leahy P, Kaminski HJ.
Invest Ophthalmol Vis Sci. 2010 Jan;51(1):192-200. Epub 2009 Aug 6.
PMID 19661226
Thy-1 binds to integrin beta(3) on astrocytes and triggers formation of focal contact sites.
Leyton L, Schneider P, Labra CV, Ruegg C, Hetz CA, Quest AF, Bron C.
Curr Biol. 2001 Jul 10;11(13):1028-38.
PMID 11470407
Phosphatidylinositol is the membrane-anchoring domain of the Thy-1 glycoprotein.
Low MG, Kincade PW.
Nature. 1985 Nov 7-13;318(6041):62-4.
PMID 2865681
THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma.
Lung HL, Bangarusamy DK, Xie D, Cheung AK, Cheng Y, Kumaran MK, Miller L, Liu ET, Guan XY, Sham JS, Fang Y, Li L, Wang N, Protopopov AI, Zabarovsky ER, Tsao SW, Stanbridge EJ, Lung ML.
Oncogene. 2005 Sep 29;24(43):6525-32.
PMID 16007174
Mice lacking the cell adhesion molecule Thy-1 fail to use socially transmitted cues to direct their choice of food.
Mayeux-Portas V, File SE, Stewart CL, Morris RJ.
Curr Biol. 2000 Jan 27;10(2):68-75.
PMID 10662668
Human thy-1: unusual localization and possible functional significance in lymphoid tissues.
McKenzie JL, Fabre JW.
J Immunol. 1981 Mar;126(3):843-50.
PMID 7462633
Thy-1 antigen mediates apoptosis of rat glomerular cells in vitro and in vivo.
Morita H, Isobe K, Cai Z, Miyazaki T, Matsumoto Y, Shinzato T, Yoshikai Y, Kimata K, Maeda K.
Nephron. 1996;73(2):293-8.
PMID 8773358
Normal spatial learning despite regional inhibition of LTP in mice lacking Thy-1.
Nosten-Bertrand M, Errington ML, Murphy KP, Tokugawa Y, Barboni E, Kozlova E, Michalovich D, Morris RG, Silver J, Stewart CL, Bliss TV, Morris RJ.
Nature. 1996 Feb 29;379(6568):826-9.
PMID 8587606
Differential expression of interleukin 1 alpha by Thy-1+ and Thy-1- lung fibroblast subpopulations: enhancement of interleukin 1 alpha production by tumor necrosis factor-alpha.
Phipps RP, Baecher C, Frelinger JG, Penney DP, Keng P, Brown D.
Eur J Immunol. 1990 Aug;20(8):1723-7.
PMID 1976521
J Exp Med. 1964 Sep 1;120:413-33.
PMID 14207060
Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses.
Rege TA, Hagood JS.
Biochim Biophys Acta. 2006 Oct;1763(10):991-9. Epub 2006 Aug 18. (REVIEW)
PMID 16996153
Thy-1, via its GPI anchor, modulates Src family kinase and focal adhesion kinase phosphorylation and subcellular localization, and fibroblast migration, in response to thrombospondin-1/hep I.
Rege TA, Pallero MA, Gomez C, Grenett HE, Murphy-Ullrich JE, Hagood JS.
Exp Cell Res. 2006 Nov 15;312(19):3752-67. Epub 2006 Sep 12.
PMID 17027000
A ligand of human thy-1 is localized on polymorphonuclear leukocytes and monocytes and mediates the binding to activated thy-1-positive microvascular endothelial cells and fibroblasts.
Saalbach A, Haustein UF, Anderegg U.
J Invest Dermatol. 2000 Nov;115(5):882-8.
PMID 11069627
Evidence from neuronal heterokaryons for a trans-acting factor suppressing Thy-1 expression during neuronal development.
Saleh M, Bartlett PF.
J Neurosci Res. 1989 Aug;23(4):406-15.
PMID 2570164
Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis.
Sanders YY, Pardo A, Selman M, Nuovo GJ, Tollefsbol TO, Siegal GP, Hagood JS.
Am J Respir Cell Mol Biol. 2008 Nov;39(5):610-8. Epub 2008 Jun 12.
PMID 18556592
T-cell-activating monoclonal antibodies, reacting with both leukocytes and erythrocytes, recognize the guinea pig Thy-1 differentiation antigen: characterization and cloning of guinea pig CD90.
Schafer H, Bartels T, Hahn G, Otto A, Burger R.
Cell Immunol. 1999 Nov 1;197(2):116-28.
PMID 10607429
Changes in Thy1 gene expression associated with damaged retinal ganglion cells.
Schlamp CL, Johnson EC, Li Y, Morrison JC, Nickells RW.
Mol Vis. 2001 Aug 15;7:192-201.
PMID 11509915
Antigenic changes in lymph-node cells after administration of antiserum to thymus cells.
Schlesinger M, Yron I.
Science. 1969 Jun 20;164(886):1412-3.
PMID 5783714
Molecular targets in pulmonary fibrosis: the myofibroblast in focus.
Scotton CJ, Chambers RC.
Chest. 2007 Oct;132(4):1311-21. (REVIEW)
PMID 17934117
Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody.
Seeger RC, Danon YL, Rayner SA, Hoover F.
J Immunol. 1982 Feb;128(2):983-9.
PMID 6172518
The human Thy-1 gene: structure and chromosomal location.
Seki T, Spurr N, Obata F, Goyert S, Goodfellow P, Silver J.
Proc Natl Acad Sci U S A. 1985 Oct;82(19):6657-61.
PMID 2864690
Complement-mediated killing of mesangial cells in experimental glomerulonephritis: cell death by a combination of apoptosis and necrosis.
Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Ohashi R, Sugisaki Y, Yamanaka N.
Nephron. 2000 Oct;86(2):152-60.
PMID 11014985
Transcriptional unit of the murine Thy-1 gene: different distribution of transcription initiation sites in brain.
Spanopoulou E, Giguere V, Grosveld F.
Mol Cell Biol. 1988 Sep;8(9):3847-56.
PMID 2906111
FcepsilonRI and Thy-1 domains have unique protein and lipid compositions.
Surviladze Z, Harrison KA, Murphy RC, Wilson BS.
J Lipid Res. 2007 Jun;48(6):1325-35. Epub 2007 Mar 26.
PMID 17387221
The mode of anchorage to the cell surface determines both the function and the membrane location of Thy-1 glycoprotein.
Tiveron MC, Nosten-Bertrand M, Jani H, Garnett D, Hirst EM, Grosveld F, Morris RJ.
J Cell Sci. 1994 Jul;107 ( Pt 7):1783-96.
PMID 7983148
A molecular basis for species differences in Thy-1 expression patterns.
Tokugawa Y, Koyama M, Silver J.
Mol Immunol. 1997 Dec;34(18):1263-72.
PMID 9683268
Tissue-specific control elements of the Thy-1 gene.
Vidal M, Morris R, Grosveld F, Spanopoulou E.
EMBO J. 1990 Mar;9(3):833-40.
PMID 1968831
Human Thy-1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18).
Wetzel A, Chavakis T, Preissner KT, Sticherling M, Haustein UF, Anderegg U, Saalbach A.
J Immunol. 2004 Mar 15;172(6):3850-9.
PMID 15004192
Comparative analysis of the N-glycans of rat, mouse and human Thy-1. Site-specific oligosaccharide patterns of neural Thy-1, a member of the immunoglobulin superfamily.
Williams AF, Parekh RB, Wing DR, Willis AC, Barclay AN, Dalchau R, Fabre JW, Dwek RA, Rademacher TW.
Glycobiology. 1993 Aug;3(4):339-48.
PMID 8104555
Expression of the neuronal surface glycoprotein Thy-1 does not follow appearance of its mRNA in developing mouse Purkinje cells.
Xue GP, Morris R.
J Neurochem. 1992 Feb;58(2):430-40.
PMID 1345938
The surface glycoprotein Thy-1 is excluded from growing axons during development: a study of the expression of Thy-1 during axogenesis in hippocampus and hindbrain.
Xue GP, Rivero BP, Morris RJ.
Development. 1991 May;112(1):161-76.
PMID 1685113
NK cell tolerance in mixed allogeneic chimeras.
Zhao Y, Ohdan H, Manilay JO, Sykes M.
J Immunol. 2003 Jun 1;170(11):5398-405.
PMID 12759414
Thy-1 expression regulates the ability of rat lung fibroblasts to activate transforming growth factor-beta in response to fibrogenic stimuli.
Zhou Y, Hagood JS, Murphy-Ullrich JE.
Am J Pathol. 2004 Aug;165(2):659-69.
PMID 15277239


This paper should be referenced as such :
Bradley, JE ; Hagood, JS
THY1 (Thy-1 cell surface antigen)
Atlas Genet Cytogenet Oncol Haematol. 2010;14(11):1042-1049.
Free journal version : [ pdf ]   [ DOI ]

Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 1 ]
  Head and neck: Retinoblastoma

External links

HGNC (Hugo)THY1   11801
Entrez_Gene (NCBI)THY1    Thy-1 cell surface antigen
AliasesCD90; CDw90
GeneCards (Weizmann)THY1
Ensembl hg19 (Hinxton)ENSG00000154096 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000154096 [Gene_View]  ENSG00000154096 [Sequence]  chr11:119415476-119423172 [Contig_View]  THY1 [Vega]
ICGC DataPortalENSG00000154096
TCGA cBioPortalTHY1
AceView (NCBI)THY1
Genatlas (Paris)THY1
SOURCE (Princeton)THY1
Genetics Home Reference (NIH)THY1
Genomic and cartography
GoldenPath hg38 (UCSC)THY1  -     chr11:119415476-119423172 -  11q23.3   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)THY1  -     11q23.3   [Description]    (hg19-Feb_2009)
GoldenPathTHY1 - 11q23.3 [CytoView hg19]  THY1 - 11q23.3 [CytoView hg38]
genome Data Viewer NCBITHY1 [Mapview hg19]  
Gene and transcription
Genbank (Entrez)AB209209 AF261093 AK057865 AK090644 AK090996
RefSeq transcript (Entrez)NM_001311160 NM_001311162 NM_001372050 NM_006288
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)THY1
Alternative Splicing GalleryENSG00000154096
Gene ExpressionTHY1 [ NCBI-GEO ]   THY1 [ EBI - ARRAY_EXPRESS ]   THY1 [ SEEK ]   THY1 [ MEM ]
Gene Expression Viewer (FireBrowse)THY1 [ Firebrowse - Broad ]
GenevisibleExpression of THY1 in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)7070
GTEX Portal (Tissue expression)THY1
Human Protein AtlasENSG00000154096-THY1 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP04216   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP04216  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP04216
Splice isoforms : SwissVarP04216
Domaine pattern : Prosite (Expaxy)IG_LIKE (PS50835)   
Domains : Interpro (EBI)Ig-like_dom    Ig-like_dom_sf    Ig-like_fold    Ig_V-set    Immunoglobulin    THY1   
Domain families : Pfam (Sanger)ig (PF00047)   
Domain families : Pfam (NCBI)pfam00047   
Domain families : Smart (EMBL)IGv (SM00406)  
Conserved Domain (NCBI)THY1
Blocks (Seattle)THY1
Human Protein Atlas [tissue]ENSG00000154096-THY1 [tissue]
Peptide AtlasP04216
IPIIPI00022892   IPI00555577   IPI00016796   IPI00982789   IPI00984294   IPI00983621   IPI00984778   
Protein Interaction databases
IntAct (EBI)P04216
Ontologies - Pathways
Ontology : AmiGOangiogenesis  angiogenesis  regulation of cell-matrix adhesion  positive regulation of cellular extravasation  GTPase activator activity  GTPase activator activity  integrin binding  integrin binding  integrin binding  protein binding  extracellular region  endoplasmic reticulum  cytosol  plasma membrane  plasma membrane  integral component of plasma membrane  focal adhesion  negative regulation of protein kinase activity  negative regulation of protein kinase activity  cytoskeleton organization  cytoskeleton organization  integrin-mediated signaling pathway  cell-cell signaling  external side of plasma membrane  cell surface  apical plasma membrane  protein kinase binding  negative regulation of cell migration  negative regulation of cell migration  dendrite  growth cone  axolemma  anchored component of external side of plasma membrane  dendrite membrane  neuronal cell body membrane  positive regulation of heterotypic cell-cell adhesion  GPI anchor binding  GPI anchor binding  receptor clustering  positive regulation of GTPase activity  positive regulation of GTPase activity  membrane raft  membrane raft  retinal cone cell development  retinal cone cell development  protein autophosphorylation  focal adhesion assembly  focal adhesion assembly  negative regulation of axonogenesis  negative regulation of axonogenesis  T cell receptor signaling pathway  T cell receptor signaling pathway  negative regulation of T cell receptor signaling pathway  positive regulation of T cell activation  positive regulation of T cell activation  positive regulation of release of sequestered calcium ion into cytosol  positive regulation of release of sequestered calcium ion into cytosol  positive regulation of focal adhesion assembly  negative regulation of protein tyrosine kinase activity  extracellular exosome  negative regulation of neuron projection regeneration  cell-cell adhesion  regulation of Rho-dependent protein serine/threonine kinase activity  
Ontology : EGO-EBIangiogenesis  angiogenesis  regulation of cell-matrix adhesion  positive regulation of cellular extravasation  GTPase activator activity  GTPase activator activity  integrin binding  integrin binding  integrin binding  protein binding  extracellular region  endoplasmic reticulum  cytosol  plasma membrane  plasma membrane  integral component of plasma membrane  focal adhesion  negative regulation of protein kinase activity  negative regulation of protein kinase activity  cytoskeleton organization  cytoskeleton organization  integrin-mediated signaling pathway  cell-cell signaling  external side of plasma membrane  cell surface  apical plasma membrane  protein kinase binding  negative regulation of cell migration  negative regulation of cell migration  dendrite  growth cone  axolemma  anchored component of external side of plasma membrane  dendrite membrane  neuronal cell body membrane  positive regulation of heterotypic cell-cell adhesion  GPI anchor binding  GPI anchor binding  receptor clustering  positive regulation of GTPase activity  positive regulation of GTPase activity  membrane raft  membrane raft  retinal cone cell development  retinal cone cell development  protein autophosphorylation  focal adhesion assembly  focal adhesion assembly  negative regulation of axonogenesis  negative regulation of axonogenesis  T cell receptor signaling pathway  T cell receptor signaling pathway  negative regulation of T cell receptor signaling pathway  positive regulation of T cell activation  positive regulation of T cell activation  positive regulation of release of sequestered calcium ion into cytosol  positive regulation of release of sequestered calcium ion into cytosol  positive regulation of focal adhesion assembly  negative regulation of protein tyrosine kinase activity  extracellular exosome  negative regulation of neuron projection regeneration  cell-cell adhesion  regulation of Rho-dependent protein serine/threonine kinase activity  
Pathways : KEGGLeukocyte transendothelial migration   
REACTOMEP04216 [protein]
REACTOME PathwaysR-HSA-163125 [pathway]   
NDEx NetworkTHY1
Atlas of Cancer Signalling NetworkTHY1
Wikipedia pathwaysTHY1
Orthology - Evolution
GeneTree (enSembl)ENSG00000154096
Phylogenetic Trees/Animal Genes : TreeFamTHY1
Homologs : HomoloGeneTHY1
Homology/Alignments : Family Browser (UCSC)THY1
Gene fusions - Rearrangements
Fusion : Fusion_HubCOL6A3--THY1    NEFM--THY1    THY1--CD38    THY1--CD44    THY1--ETS1    THY1--HLA-B    THY1--LUZP2    THY1--VIM-AS1    USP12--THY1   
Fusion : QuiverTHY1
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerTHY1 [hg38]
Exome Variant ServerTHY1
GNOMAD BrowserENSG00000154096
Varsome BrowserTHY1
Genomic Variants (DGV)THY1 [DGVbeta]
DECIPHERTHY1 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisTHY1 
ICGC Data PortalTHY1 
TCGA Data PortalTHY1 
Broad Tumor PortalTHY1
OASIS PortalTHY1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICTHY1  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DTHY1
Mutations and Diseases : HGMDTHY1
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch THY1
DgiDB (Drug Gene Interaction Database)THY1
DoCM (Curated mutations)THY1 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)THY1 (select a term)
NCG6 (London) select THY1
Cancer3DTHY1(select the gene name)
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Genetic Testing Registry THY1
NextProtP04216 [Medical]
Target ValidationTHY1
Huge Navigator THY1 [HugePedia]
Clinical trials, drugs, therapy
Protein Interactions : CTD
Pharm GKB GenePA36510
Clinical trialTHY1
canSAR (ICR)THY1 (select the gene name)
DataMed IndexTHY1
PubMed206 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Feb 19 18:01:41 CET 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us